secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-202288
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q2 net loss narrows to $21.1M; revenue jumps to $22.1M on GSK collaboration
--------------------------------------------------------------------------------

- Net loss of $21.1M vs $41.3M YoY; revenue of $22.1M from GSK/Takeda collaborations vs $0.4M in Q2 2022.
- Cash and equivalents $173.0M at June 30, 2023, up from $88.5M at Dec 2022; runway into 2025.
- Imminent CTA submission for WVE-006 (AATD RNA editing candidate); first-in-human study expected 2H 2023.
- DMD candidate WVE-N531 on track for potentially registrational Phase 2 dosing in 2H 2023; dystrophin data in 2024.
- Discontinued WVE-004 for C9-ALS/FTD, but biomarker data validated PN chemistry; HD candidate WVE-003 multi-dose dosing underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/0001193125-23-202288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/d584115d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-202288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer